Sigma-1 Receptor Agonists Inhibit Oligodendrocyte Cytotoxicity Induced by Molecules Involved in Cell Damage in Multiple Sclerosis.

New Alzheimer’s Drug ANAVEX 2-73: A Phase 2a Study, Clinical Safety, Tolerability and Maximum Tolerated Dose finding in mild-to-moderate Alzheimer’s Patients.